Immunic, Inc. (IMUX) Q1 FY26 Earnings Call

April 2025 CALIPER data is the next major value inflection, with potential to support treatment in non-relapsing secondary progressive MS [6].

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-03-31
Length44 minutes
EPS$-1.08
EPS consensus$-0.71
Revenue$760000.00

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All IMUX earnings ยท Back to IMUX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.